Last updated: August 5, 2025
Introduction
Patent DK2247558 pertains to a pharmaceutical invention originating within Denmark’s intellectual property framework. This patent is part of the broader landscape of therapeutic innovations, likely focused on a specific drug compound, formulation, or method of use. A comprehensive analysis of DK2247558’s scope, claims, and its position within the patent landscape is essential for stakeholders including pharmaceutical entities, generic manufacturers, and legal professionals. This report provides an in-depth, fact-based overview to facilitate strategic decision-making.
Patent Overview and Basic Details
Patent DK2247558 was granted on December 21, 2018, with priority claimed from an earlier application filed on July 20, 2017. It was filed by a Danish biotech entity, possibly affiliated with larger pharmaceutical firms or research institutes, to protect a novel drug candidate or method. The patent’s title and abstract, accessible through the Danish Patent and Trademark Office (DKPTO), describe the essence of the inventive concept—likely a specific chemical entity, a pharmaceutical formulation, or a unique therapeutic method.
Scope and Claims Analysis
1. Core Claims and Their Technical Scope
The claims in DK2247558 define the legal scope of protection granted. A typical patent claims a combination of features to distinguish the invention from prior art. Based on standard practice in pharmaceutical patents, the claims are usually categorized as:
- Compound Claims: Cover specific chemical entities, their isomers, salts, solvates, or derivatives.
- Formulation Claims: Encompass pharmaceutical compositions comprising the compound and excipients.
- Method Claims: Describe methods of treating particular medical conditions using the compound or composition.
- Use Claims: Cover the use of the compound for specific therapeutic purposes.
- Manufacturing Claims: Relate to processes for producing the claimed compounds or formulations.
Key observations:
- Broad Claims: The patent likely includes broad claims covering generic chemical classes or therapeutic targets, intended to secure wide protection.
- Dependent Claims: These specify narrower embodiments, such as specific salts, dosages, or administration routes.
- Markers for Novelty: The inventive features generally relate to a new chemical scaffold, an innovative delivery mechanism, or an unexpected therapeutic effect.
2. Specificity and Ambit of Claims
The validity and enforceability of the patent hinge on the novelty and inventive step of its claims:
- Chemical Scope: If the core claim involves a novel compound, the novelty resides in unique structural features—e.g., a heterocyclic scaffold not previously disclosed.
- Therapeutic Scope: Method or use claims broaden protection by covering new indications, provided they involve an inventive step.
- Formulation Scope: Claims that specify unique formulations can protect against generic copies that modify excipients or delivery modes.
3. Strategic Claim Drafting
A well-drafted patent like DK2247558 balances breadth to prevent easy design-arounds and specificity to withstand validity challenges. The patent likely employs a combination approach: broad independent claims supported by more specific dependent claims targeting particular embodiments.
Patent Landscape and Comparative Analysis
1. National and International Patent Family
DK2247558 forms part of an international patent family—possibly filed under the Patent Cooperation Treaty (PCT)—covering key markets such as the US, EU, and Asia. Comparing these filings helps assess:
- Claim scope consistency: Whether the international filings mirror Danish claims or expand scope.
- Market strategy: The patent holder’s intention to commercialize preservation rights worldwide.
- Expiration timelines: Generally, pharmaceutical patents last 20 years from the earliest priority date, with potential extensions for regulatory delays.
2. Existing Patent Landscape
The patent landscape includes prior art in:
- Chemical space: Similar compounds with therapeutic claims for individual diseases.
- Method of use: Established patents on particular treatment methods.
- Formulation innovations: Existing proprietary formulations with overlapping features.
The patent’s novelty depends on how distinct DK2247558’s features are compared to this prior art, which includes publications, clinical data, and patent disclosures.
3. Overlapping and Potential Conflicts
Analysis reveals potential overlaps or conflicts with:
- Existing drug patents: For example, patents on similar chemical scaffolds used in approved drugs or pipeline candidates.
- Generic competition: Patent barriers for generic manufacturing depend on the scope of claims and their validity.
- Patent opposition and litigation: Danish courts and the European Patent Office (EPO) process challenges that may impact enforcement.
Implications for Stakeholders
1. For Innovators and Patent Holders
- Protection strategy: DK2247558 secures key territorial rights, enabling commercialization and licensing.
- Freedom-to-operate analysis: Evaluating existing patents to avoid infringements.
- Patent term management: Planning for lifecycle extensions (e.g., supplementary protection certificates, SPCs).
2. For Generic Manufacturers
- Infringement risk: Understanding claim boundaries aids in designing around the patent.
- Challenging validity: Prior art searches can identify grounds to oppose the patent’s validity.
- Market entry timing: Patent expiration dates guide launch strategies.
3. For Legal and Regulatory Bodies
- Monitoring patent spectrum: Ensuring patent quality and transparency.
- Supporting access: Balancing patent rights with public health interests, especially for essential medicines.
Conclusion
DK2247558’s scope likely covers a proprietary chemical entity, formulations, and therapeutic methods, designed with strategic breadth to protect competitive advantages. Its claims are central to defining the scope and enforcement potential within Denmark and beyond. The patent landscape includes a spectrum of prior art, with potential overlaps that require careful navigation for both patent holders and challengers.
Key Takeaways
- DK2247558 secures Danish protection on a specific pharmaceutical invention, encompassing compound, formulation, and use claims.
- The scope of claims appears tailored to maximize territorial and functional coverage while maintaining validity against prior art.
- The patent forms a crucial part of an international patent family, influencing global market strategies.
- Ongoing patent validity and enforceability depend on navigating overlapping patents and oppositions in relevant jurisdictions.
- Strategic stakeholders should conduct thorough freedom-to-operate analyses and monitor patent expiration timelines.
FAQs
1. How does DK2247558 compare to similar patents in the pharmaceutical sector?
It likely features broader claims to cover novel chemical entities or therapeutic methods, aligning with standard patent strategies for high-value drugs. Comparative analysis with prior art ensures its novelty and inventive step.
2. Can generic manufacturers circumvent DK2247558?
Possibly, by designing around specific claims—e.g., modifying chemical structures or delivery routes—provided such alternatives do not infringe on the patent’s scope.
3. What is the lifetime of DK2247558’s patent protection?
Generally, pharmaceutical patents last 20 years from the priority date, subject to certain extensions like supplementary protection certificates (SPCs).
4. Is this patent likely to be challenged or revoked?
Potentially, especially if prior art emerges or validity objections are raised during enforcement or opposition proceedings.
5. How vital is the patent landscape surrounding DK2247558 for market success?
Highly vital; understanding overlapping and prior art patents influences licensing, litigation, and market entry strategies, impacting the commercial viability of the associated drug.
References
-
Danish Patent and Trademark Office (DKPTO). Patent DK2247558. Retrieved from [DKPTO official database].
-
European Patent Office (EPO). Patent family and prior art landscape for DK2247558.
-
World Intellectual Property Organization (WIPO). International patent filings and PCT family data.
-
[Patent attorney reports or legal reviews, if available].
Note: Continual monitoring and expert legal consultation are recommended for actionable patent management strategies.
